Diabetic Foot Infection Clinical Trial
Official title:
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Verified date | May 2021 |
Source | Tissue Tech Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It is hypothesized that application of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer will, with concomitant management of infection, result in a higher proportion of wounds showing complete healing within 16 weeks of initiating therapy.
Status | Completed |
Enrollment | 32 |
Est. completion date | April 1, 2019 |
Est. primary completion date | January 10, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - The subject has signed the informed consent form - The subject is male or female, at least 18 years of age inclusive at the date of Screening - The subject has confirmed diagnosis of Type I or Type II diabetes - The subject's index ulcer is located on the plantar surface, inter digital, heel, or lateral or medial surface of the foot - The subject has an index ulcer with visible margins having an area =1.0 cm2 to = 10.0 cm2 when measured by the electronic measuring device at Screening - The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule - The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (x-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis - The subject has an Ankle Brachial Index = 0.7 to = 1.3 or TcPO2 = 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure = 50 mmHg - The subject is under the care of a physician for the management of Diabetes Mellitus Exclusion Criteria: - The subject's index ulcer is primarily located on the dorsal surface of the foot - The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure - The subject has a glycated hemoglobin A1c (HbA1c) level of > 12% - The subject has a serum albumin level = 2.0 g/dL - The subject has a white blood cell count < 2.0 x109/L, neutrophils < 1.0 x109/L, or platelets < 100 x109/L - The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening - The subject is pregnant - The subject is a nursing mother - The subject's index ulcer is over an active Charcot deformity - The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer - Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina | Chapel Hill | North Carolina |
United States | Futuro Clinical Trials, LLC | McAllen | Texas |
United States | University of Miami | Miami | Florida |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Ochsner Medical Center | New Orleans | Louisiana |
United States | St Luke's-Roosevelt Hospital Center | New York | New York |
United States | Rosalind Franklin University | North Chicago | Illinois |
United States | Banner University Medical Center | Phoenix | Arizona |
United States | Carilion Clinic | Roanoke | Virginia |
United States | Village Podiatry Centers | Smyrna | Georgia |
United States | UCLA Olive View | Sylmar | California |
Lead Sponsor | Collaborator |
---|---|
Tissue Tech Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects With Complete Wound Healing | Proportion of subjects with complete wound healing observed over the 16-week treatment period. Complete wound healing was defined as an initial observation of closure, followed by two confirmatory visits two weeks apart. | 16-weeks | |
Secondary | Time to Complete Wound Healing | Time in number of days to complete wound closure over the 16 week treatment period, starting from enrollment to the time of the initial observation of wound closure | up to 16 weeks | |
Secondary | Percent Change in Wound Surface Area | Rate of wound closure, specifically percent change in the wound surface area (cm2) at each visit from baseline for assessing the rate of wound closure in area. Only percent change in wound surface area at week 16 reported. | at week 16 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Recruiting |
NCT05613985 -
PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers
|
N/A | |
Recruiting |
NCT03964571 -
Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients
|
N/A | |
Completed |
NCT05616351 -
Antibiotic Therapy in Infections of the Diabetic Foot Syndrome
|
||
Recruiting |
NCT05948592 -
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
|
Phase 2 | |
Recruiting |
NCT04714411 -
Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
|
||
Completed |
NCT05243810 -
EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers
|
N/A | |
Recruiting |
NCT05610865 -
Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers
|
Phase 1 | |
Recruiting |
NCT04450693 -
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
|
Phase 3 | |
Recruiting |
NCT05369052 -
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
|
Phase 3 | |
Completed |
NCT02723539 -
A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI
|
Phase 1 | |
Completed |
NCT04440839 -
Implementation of Telemedicine for Patient With Lower Extremity Wounds
|
N/A | |
Withdrawn |
NCT04289948 -
Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT03495349 -
Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
|
||
Completed |
NCT05564728 -
Diabetes Footcare Companion App for Patients and Carers
|
||
Withdrawn |
NCT03354806 -
Peripheral Analgesia in Painful Diabetic Neuropathy
|
N/A | |
Completed |
NCT01594762 -
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
|
Phase 3 | |
Completed |
NCT01590758 -
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
|
Phase 3 | |
Active, not recruiting |
NCT05174806 -
Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients
|
Phase 2 | |
Recruiting |
NCT04141787 -
Ceftriaxone as Home IV for Staph Infections
|
Phase 4 |